Vedana Therapeutics

Vedana Therapeutics is a private biotechnology company developing next-generation preventive therapies for migraine. The company emerged from stealth in June 2026 with a $46 million Series A financing and is focused on long-acting, subcutaneously delivered antibody medicines aimed at clinically validated migraine pathways beyond first-generation CGRP approaches. Its lead pipeline includes an anti-PACAP monoclonal antibody and a bispecific PACAP x CGRP antibody, both intended for at-home self-injection and improved migraine control. Vedana is led by executives and advisors with prior experience developing major migraine biologics, including CGRP- and PACAP-directed programs.